Given the well-characterized, manageable, and reversible nature of thrombocytopenia with bortezomib, platelet transfusion support rather than dose reduction, particularly in the first 2 cycles ...

In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance ...

Bortezomib (a proteasome inhibitor) has recently been approved for treatment of relapsed multiple myeloma, a plasma cell neoplasia, owing to the sensitivity of immunoglobulin-synthesizing myeloma ...

Nexpovio (selinexor) – which is sold as Xpovio in some markets – is a first-in-class nuclear export XPO1 inhibitor that was ...

During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a ...

Lee et al. assessed the efficacy of the proteasome inhibitor bortezomib on collagen-induced arthritis (CIA), a mouse model of rheumatoid arthritis. Two doses of type II collagen, administered 2 ...

As mentioned in the previous business update dated August 2, 2023, opportunities Waverley Pharma envisioned of marketing generic oncology drugs capecitabine, temozolomide, bortezomib and pemetrexed in ...

The data from this study showed that treatment with Blenrep in combination with bortezomib plus dexamethasone (BorDex) led to a statistically significant PFS benefit (extending the time to disease ...

Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of ...

FORUS Therapeutics Inc. ("FORUS") is deeply disappointed and disagrees with the recent decision by the Honourable Christian ...

Concurrently, Sanofi said its Phase 3 IMROZ trial of Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) met its primary endpoint at a ...

Bortezomib, a novel proteasome inhibitor, is approved for the treatment of patients with multiple myeloma who have received at least 1 prior therapy. In the assessment of proteasome inhibition for ...